

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT3150334

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT

CONVEYING PARTY DATA

Name	Execution Date
CHRONTECH PHARMA AB	12/10/2014

RECEIVING PARTY DATA

Name:	TRIEPEP AB
Street Address:	HÄLSOVÄGEN 7
City:	HUDDINGE
State/Country:	SWEDEN
Postal Code:	SE-141 57

PROPERTY NUMBERS Total: 43

Property Type	Number
Patent Number:	6680059
Patent Number:	7261883
Patent Number:	7244422
Patent Number:	6858590
Patent Number:	7241440
Patent Number:	7244715
Patent Number:	6960569
Patent Number:	7439347
Patent Number:	7226912
Patent Number:	7022830
Patent Number:	7307066
Patent Number:	7223743
Patent Number:	7638499
Patent Number:	7943149
Patent Number:	8163547
Patent Number:	8163712
Patent Number:	8158602
Application Number:	13441305
Patent Number:	7566812
Patent Number:	8071561
Patent Number:	8883169

PATENT

Property Type	Number
Application Number:	14527669
Patent Number:	8258275
Patent Number:	8445663
Application Number:	13856271
Patent Number:	5869232
Patent Number:	6660842
Patent Number:	7019111
Patent Number:	6040137
Patent Number:	6245895
Patent Number:	6933366
Patent Number:	7318926
Patent Number:	7332166
Patent Number:	8303956
Patent Number:	8658179
Application Number:	14085167
Patent Number:	7335359
Patent Number:	7534435
Patent Number:	7968697
Application Number:	13514269
Application Number:	13511353
Application Number:	14221662
Application Number:	14125905

CORRESPONDENCE DATA

Fax Number: (949)760-9502

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 949-760-0404

Email: efilings@knobbe.com

Correspondent Name: KNOBBE MARTENS OLSON & BEAR LLP

Address Line 1: 2040 MAIN STREET

Address Line 2: 14TH FLOOR

Address Line 4: IRVINE, CALIFORNIA 92614

ATTORNEY DOCKET NUMBER:	TRIEPEP.000GEN
NAME OF SUBMITTER:	ERIC S. FURMAN
SIGNATURE:	/Eric Furman/
DATE SIGNED:	12/16/2014

Total Attachments: 10
source=Assignment#page1.tif
source=Assignment#page2.tif

source=Assignment#page3.tif
source=Assignment#page4.tif
source=Assignment#page5.tif
source=Assignment#page6.tif
source=Assignment#page7.tif
source=Assignment#page8.tif
source=Assignment#page9.tif
source=Assignment#page10.tif

ASSIGNMENT



WHEREAS, CHRONTECH PHARMA AB, a Swedish company having offices at Hälsovägen 7, Huddinge, SE-141 57, Sweden (hereinafter "ASSIGNOR") represents and warrants that it is the sole owner of the entire right, title, and interest to the patents and patent applications set forth in Schedule 1 ("the Patents").

WHEREAS, TRIPEP AB, a Swedish company having offices at Hälsovägen 7, Huddinge, SE-141 57, Sweden (hereinafter "ASSIGNEE"), desires to acquire the entire right, title, and interest in and to the inventions disclosed in the Patents.

NOW, THEREFORE, for good and valuable consideration, the receipt of which is hereby acknowledged, ASSIGNOR hereby further acknowledges that it has sold, assigned, and transferred, and by these presents does hereby sell, assign, and transfer, unto ASSIGNEE, its successors, legal representatives, and assigns, the entire right, title, and interest to the said Patents and all National Patents that may be granted thereon, and all divisions, continuations, continuations-in-part, designs, and extensions thereof, and all rights of priority under International Conventions and any applications for Letters Patent that may hereafter be filed stemming from said Patents in any country; and ASSIGNOR hereby authorizes and requests any Official of any country, whose duty it is to issue National Patents stemming from the Patents, to issue all Letters Patent to ASSIGNEE, its successors, legal representatives, and assigns, in accordance with the terms of this Agreement.

ASSIGNOR does hereby sell, assign, transfer, and convey to ASSIGNEE, its successors, legal representatives, and assigns all claims for damages and all remedies arising out of any violation of the rights assigned hereby that may have accrued prior to the date of assignment to ASSIGNEE, or may accrue hereafter, including, but not limited to, the right to sue for, collect, and retain damages for past infringements of the said Patent before or after issuance;

AND ASSIGNOR DOES HEREBY covenant and agree that ASSIGNOR will communicate to said ASSIGNEE, its successors, legal representatives, and assigns, any facts known to ASSIGNOR respecting the Patents, and testify in any legal proceeding, assist in the preparation of any divisional applications relating to the Patents, sign all lawful papers, authorize the filing of and execute and make all rightful oaths and/or declarations in connection with the Patents and any divisional applications stemming therefrom, and generally do everything possible to aid the ASSIGNEE, its successors, legal representatives, and assigns, to obtain and enforce proper patent protection for the Patents in all countries.

<p>_____ CHRONTECH PHARMA AB</p> <p>By: </p> <p>Name Printed: <u>Anders Vahlne, Matti Sillberg</u></p> <p>Title: <u>CEO ; director (MS)</u></p> <p>Date: <u>Dec. 10TH 2014</u></p>	<p>_____ TRIPEP AB</p> <p>By: </p> <p>Name Printed: <u>Anders Vahlne</u></p> <p>Title: <u>Director</u></p> <p>Date: <u>Dec. 10TH 2014</u></p>
--	--

SCHEDULE 1

Case Number	Title	Country	App. No. or Patent No.
TRIPEP.23AUSC1	VACCINES CONTAINING RIBAVIRIN AND METHODS OF USE THEREOF	USA	6,680,059
TRIPEP.23AUSC2	VACCINES CONTAINING RIBAVIRIN AND METHODS OF USE THEREOF	USA	7,261,883
TRIPEP.23AUSC2C	VACCINES CONTAINING RIBAVIRIN AND METHODS OF USE THEREOF	USA	7,244,422
TRIPEP.23AUS2	VACCINES CONTAINING RIBAVIRIN AND METHODS OF USE THEREOF	USA	6,858,590
TRIPEP.23AUS2C1	VACCINES CONTAINING RIBAVIRIN AND METHODS OF USE THEREOF	USA	7,241,440
TRIPEP.23AUS2CC	VACCINES CONTAINING RIBAVIRIN AND METHODS OF USE THEREOF	USA	7,244,715
TRIPEP.023QAT	VACCINES CONTAINING RIBAVIRIN AND METHODS OF USE THEREOF	Austria	1311289
TRIPEP.023QAU	VACCINES CONTAINING RIBAVIRIN AND METHODS OF USE THEREOF	Australia	2001292151
TRIPEP.023QBE	VACCINES CONTAINING RIBAVIRIN AND METHODS OF USE THEREOF	Belgium	1311289
TRIPEP.023QCA	VACCINES CONTAINING RIBAVIRIN AND METHODS OF USE THEREOF	Canada	2419418
TRIPEP.023QCH	VACCINES CONTAINING RIBAVIRIN AND METHODS OF USE THEREOF	Switzerland	1311289

TRIEPEP.023QCN	VACCINES CONTAINING RIBAVIRIN AND METHODS OF USE THEREOF	China	ZL01815071.3
TRIEPEP.023QDE	VACCINES CONTAINING RIBAVIRIN AND METHODS OF USE THEREOF	Germany	60130999
TRIEPEP.023QES	VACCINES CONTAINING RIBAVIRIN AND METHODS OF USE THEREOF	Spain	1311289
TRIEPEP.023QFR	VACCINES CONTAINING RIBAVIRIN AND METHODS OF USE THEREOF	France	1311289
TRIEPEP.023QGB	VACCINES CONTAINING RIBAVIRIN AND METHODS OF USE THEREOF	Great Britain	1311289
TRIEPEP.023QIE	VACCINES CONTAINING RIBAVIRIN AND METHODS OF USE THEREOF	Ireland	1311289
TRIEPEP.023QIT	VACCINES CONTAINING RIBAVIRIN AND METHODS OF USE THEREOF	Italy	1311289
TRIEPEP.023QJP	VACCINES CONTAINING RIBAVIRIN AND METHODS OF USE THEREOF	Japan	5175417
TRIEPEP.023QKR	VACCINES CONTAINING RIBAVIRIN AND METHODS OF USE THEREOF	Republic of Korea (South)	10-0801123
TRIEPEP.023QRAU	VACCINES CONTAINING RIBAVIRIN AND METHODS OF USE THEREOF	Australia	2006203358
TRIEPEP.023QRCH	HCVNS3/4A ENCODING NUCLEIC ACID	Switzerland	1947185
TRIEPEP.023QRDE	HCVNS3/4A ENCODING NUCLEIC ACID	Germany	1947185
TRIEPEP.023QRES	HCVNS3/4A ENCODING NUCLEIC ACID	Spain	1947185
TRIEPEP.023QRFR	HCVNS3/4A ENCODING NUCLEIC ACID	France	1947185
TRIEPEP.023QRGB	HCVNS3/4A ENCODING NUCLEIC ACID	United Kingdom	1947185
TRIEPEP.023QRIE	HCVNS3/4A ENCODING NUCLEIC ACID	Ireland	1947185
TRIEPEP.023QRIT	HCVNS3/4A ENCODING NUCLEIC ACID	Italy	1947185

TRIEPEP.028AUS	A HEPATITIS C VIRUS NON-STRUCTURAL NS3/4A FUSION GENE	USA	6,960,569
TRIEPEP.028C1	A HEPATITIS C VIRUS NON-STRUCTURAL NS3/4A FUSION GENE	USA	7,439,347
TRIEPEP.028C1C1	A HEPATITIS C VIRUS NON-STRUCTURAL NS3/4A FUSION GENE	USA	7,226,912
TRIEPEP.028CP1	A HEPATITIS C VIRUS NON-STRUCTURAL NS3/4A FUSION GENE	USA	7,022,830
TRIEPEP.028CP1C1	HEPATITIS C VIRUS CODON OPTIMIZED NON- STRUCTURAL NS3/4A FUSION GENE	USA	7,307,066
TRIEPEP.28CP1C1C	HEPATITIS C VIRUS CODON OPTIMIZED NON- STRUCTURAL NS3/4A FUSION GENE	USA	7,223,743
TRIEPEP.28CPC1C2	HEPATITIS C VIRUS CODON OPTIMIZED NON- STRUCTURAL NS3/4A FUSION GENE	USA	7,638,499
TRIEPEP.28CPC1C3	HEPATITIS C VIRUS CODON OPTIMIZED NON- STRUCTURAL NS3/4A FUSION GENE	USA	7,943,149
TRIEPEP.28CPC1C4	HEPATITIS C VIRUS CODON OPTIMIZED NON- STRUCTURAL NS3/4A FUSION GENE	USA	8,163,547
TRIEPEP.28CPC1C5	HEPATITIS C VIRUS CODON OPTIMIZED NON- STRUCTURAL NS3/4A FUSION GENE	USA	8,163,712
TRIEPEP.28CPC1C6	HEPATITIS C VIRUS CODON OPTIMIZED NON- STRUCTURAL NS3/4A FUSION GENE	USA	8,158,602
TRIEPEP.28P1C8	HEPATITIS C VIRUS CODON OPTIMIZED NON- STRUCTURAL NS3/4A FUSION GENE	USA	13/441305
TRIEPEP.028QAU	A HEPATITIS C VIRUS CODON OPTIMIZED NON- STRUCTURAL NS3/4A FUSION GENE	Australia	2003290385
TRIEPEP.028QCN	A HEPATITIS C VIRUS CODON OPTIMIZED NON- STRUCTURAL NS3/4A FUSION GENE	China	200380109208.7

TRIEPEP.028QAT	A HEPATITIS C VIRUS CODON OPTIMIZED NON- STRUCTURAL NS3/4A FUSION GENE	Austria	1567190
TRIEPEP.028QBE	A HEPATITIS C VIRUS CODON OPTIMIZED NON- STRUCTURAL NS3/4A FUSION GENE	Belgium	1567190
TRIEPEP.028QCH	A HEPATITIS C VIRUS CODON OPTIMIZED NON- STRUCTURAL NS3/4A FUSION GENE	Switzerland / Liechtenstein	1567190
TRIEPEP.028QDE	A HEPATITIS C VIRUS CODON OPTIMIZED NON- STRUCTURAL NS3/4A FUSION GENE	Germany	1567190
TRIEPEP.028QES	A HEPATITIS C VIRUS CODON OPTIMIZED NON- STRUCTURAL NS3/4A FUSION GENE	Spain	1567190
TRIEPEP.028QFR	A HEPATITIS C VIRUS CODON OPTIMIZED NON- STRUCTURAL NS3/4A FUSION GENE	France	1567190
TRIEPEP.028QGB	A HEPATITIS C VIRUS CODON OPTIMIZED NON- STRUCTURAL NS3/4A FUSION GENE	United Kingdom	1567190
TRIEPEP.028QIE	A HEPATITIS C VIRUS CODON OPTIMIZED NON- STRUCTURAL NS3/4A FUSION GENE	Ireland	1567190
TRIEPEP.028QIT	A HEPATITIS C VIRUS CODON OPTIMIZED NON- STRUCTURAL NS3/4A FUSION GENE	Italy	1567190
TRIEPEP.028QHK	A HEPATITIS C VIRUS CODON OPTIMIZED NON- STRUCTURAL NS3/4A FUSION GENE	Hong Kong	06102404.0
TRIEPEP.028QJP	A HEPATITIS C VIRUS CODON OPTIMIZED NON- STRUCTURAL NS3/4A FUSION GENE	Japan	4660195
TRIEPEP.028QKR	A HEPATITIS C VIRUS CODON OPTIMIZED NON- STRUCTURAL NS3/4A FUSION GENE	Korea	10-1144642
TRIEPEP.070NP	TRANSGENIC MOUSE MODELS OF HEPATITIS C VIRUS (HCV) AND IDENTIFICATION OF HCV THERAPEUTICS	USA	7,566,812




TRIEP.070VDE	TRANSGENIC MOUSE MODELS OF HEPATITIS C VIRUS (HCV) AND IDENTIFICATION OF HCV THERAPEUTICS	Germany	1781690
TRIEP.070VFR	TRANSGENIC MOUSE MODELS OF HEPATITIS C VIRUS (HCV) AND IDENTIFICATION OF HCV THERAPEUTICS	France	1781690
TRIEP.070VGB	TRANSGENIC MOUSE MODELS OF HEPATITIS C VIRUS (HCV) AND IDENTIFICATION OF HCV THERAPEUTICS	United Kingdom	1781690
TRIEP.111A	IMMUNOGEN PLATFORM	USA	8,071,561
TRIEP.111C1	IMMUNOGEN PLATFORM	USA	8,883,169
TRIEP.111C2	IMMUNOGEN PLATFORM	USA	14/527,669
TRIEP.111CP1C1	IMMUNOGEN PLATFORM	USA	8,258,275
TRIEP.116NP	COMPOSITIONS AND METHODS THAT ENHANCE AN IMMUNE RESPONSE	USA	8,445,663
TRIEP.116C1	COMPOSITIONS AND METHODS THAT ENHANCE AN IMMUNE RESPONSE	USA	13/856271
TRIEP.116EP	COMPOSITIONS AND METHODS THAT ENHANCE AN IMMUNE RESPONSE	Europe	10710625.4
TRIEP.116HK	CODON-OPTIMISED HEPATITIS B VIRUS CORE ANTIGEN	Hong Kong	12105381.2
TRIEP.116IN	CODON-OPTIMISED HEPATITIS B VIRUS CORE ANTIGEN	India	6734/DELNP/2011
OPSON.001AUS	ANTIGEN/ANTIBODY SPECIFICITY EXCHANGER	USA	5,869,232
OPSON.001CP3	LIGAND/RECEPTOR SPECIFICITY EXCHANGERS THAT REDIRECT ANTIBODIES TO RECEPTORS ON A PATHOGEN	USA	6,660,842



OPSON.001CP3C1	GLYCOSYLATED LIGAND/RECEPTOR SPECIFICITY EXCHANGERS SPECIFIC FOR BACTERIAL ADHESION RECEPTORS	USA	7,019,111
OPSON.001C1	ANTIGEN/ANTIBODY SPECIFICITY EXCHANGER	USA	6,040,137
OPSON.001C2	ANTIGEN/ANTIBODY SPECIFICITY EXCHANGER	USA	6,245,895
OPSON.001AUP1	SPECIFICITY EXCHANGERS THAT REDIRECT ANTIBODIES TO A PATHOGEN	USA	6,933,366
OPSON.002VAU	LIGAND/RECEPTOR SPECIFICITY EXCHANGERS THAT REDIRECT ANTIBODIES TO RECEPTORS ON A PATHOGEN	Australia	2002223973
OPSON.002VCA	LIGAND/RECEPTOR SPECIFICITY EXCHANGERS THAT REDIRECT ANTIBODIES TO RECEPTORS ON A PATHOGEN	Canada	2421877
OPSON.002VCN	LIGAND/RECEPTOR SPECIFICITY EXCHANGERS THAT REDIRECT ANTIBODIES TO RECEPTORS ON A PATHOGEN	China	ZL01816780.2
OPSON.002VRAU	LIGAND/RECEPTOR SPECIFICITY EXCHANGERS THAT REDIRECT ANTIBODIES TO RECEPTORS ON A PATHOGEN	Australia	2007203138
OPSON.002VRU	LIGAND/RECEPTOR SPECIFICITY EXCHANGERS THAT REDIRECT ANTIBODIES TO RECEPTORS ON A PATHOGEN	Russian Federation	2300391
OPSON.003A	GLYCOSYLATED SPECIFICITY EXCHANGERS	USA	7,318,926
OPSON.003C1	GLYCOSYLATED SPECIFICITY EXCHANGERS	USA	7,332,166
OPSON.003C2C1	GLYCOSYLATED SPECIFICITY EXCHANGERS	USA	8,303,956

OPSON.003D1	GLYCOSYLATED SPECIFICITY EXCHANGERS	USA	8,658,179
OPSON.003D2	GLYCOSYLATED SPECIFICITY EXCHANGERS	USA	14/085167
OPSON.003CP1	GLYCOSYLATED SPECIFICITY EXCHANGERS	USA	7,335,359
OPSON.003CP1C1	GLYCOSYLATED SPECIFICITY EXCHANGERS	USA	7,534,435
OPSON.003VAUD1	ANTIGEN/ANTIBODY OR LIGAND/RECEPTOR GLYCOSYLATED SPECIFICITY EXCHANGERS	Australia	2012200059
OPSON.003VCA	ANTIGEN/ANTIBODY OR LIGAND/RECEPTOR GLYCOSYLATED SPECIFICITY EXCHANGERS	Canada	2514270
OPSON.003VEP	ANTIGEN/ANTIBODY OR LIGAND/RECEPTOR GLYCOSYLATED SPECIFICITY EXCHANGERS	Europe	04708416.5
OPSON.003VEPD1	ANTIGEN/ANTIBODY OR LIGAND/RECEPTOR GLYCOSYLATED SPECIFICITY EXCHANGERS	Europe	10164941.6
OPSON.003VHK	ANTIGEN/ANTIBODY OR LIGAND/RECEPTOR GLYCOSYLATED SPECIFICITY EXCHANGERS	Hong Kong	06104906.9
TRIPEP.080NP	A HEPATITIS C VIRUS NON-STRUCTURAL NS3/4A FUSION GENE	USA	7,968,697
TRIPEP.104AU	CODON-OPTIMIZED HEPATITIS B VIRUS CORE ANTIGEN (HBCAG)	Australia	2010332400
TRIPEP.104CA	CODON-OPTIMIZED HEPATITIS B VIRUS CORE ANTIGEN (HBCAG)	Canada	2784488
TRIPEP.104CN	CODON-OPTIMIZED HEPATITIS B VIRUS CORE ANTIGEN (HBCAG)	China	201080062289.X

TRIEP.104EP	CODON-OPTIMIZED HEPATITIS B VIRUS CORE ANTIGEN (HBCAG)	Europe	10816307.2
TRIEP.104IN	CODON-OPTIMIZED HEPATITIS B VIRUS CORE ANTIGEN (HBCAG)	India	1451/MUMNP/2012
TRIEP.104JP	CODON-OPTIMIZED HEPATITIS B VIRUS CORE ANTIGEN (HBCAG)	Japan	Not Yet Assigned
TRIEP.104KR	CODON-OPTIMIZED HEPATITIS B VIRUS CORE ANTIGEN (HBCAG)	South Korea	Not Yet Assigned
TRIEP.104NP	CODON-OPTIMIZED HEPATITIS B VIRUS CORE ANTIGEN (HBCAG)	USA	13/514269
TRIEP.104RU	CODON-OPTIMIZED HEPATITIS B VIRUS CORE ANTIGEN (HBCAG)	Russia	2012124820
TRIEP.114EP	T CELL RECEPTORS SPECIFIC FOR AN IMMUNODOMINANT CTL EPI TOPE OF HCV	Europe	10796478.5
TRIEP.114NP	T CELL RECEPTORS SPECIFIC FOR AN IMMUNODOMINANT CTL EPI TOPE OF HCV	USA	13/511353
TRIEP.119C1	SIMPLE VACCINES FROM DNA LAUNCHED SUICIDAL FLAVIVIRUSES	USA	14/221,662
TRIEP.125AU	INJECTION NEEDLE AND DEVICE	Australia	2012270015
TRIEP.125CA	INJECTION NEEDLE AND DEVICE	Canada	2839196
TRIEP.125CN	INJECTION NEEDLE AND DEVICE	China	201280039644.0
TRIEP.125EP	INJECTION NEEDLE AND DEVICE	Europe	12737344.7
TRIEP.125IN	INJECTION NEEDLE AND DEVICE	India	10993/DELNP/2013
TRIEP.125KR	INJECTION NEEDLE AND DEVICE	Korea	10-2014-7000981
TRIEP.125NP	INJECTION NEEDLE AND DEVICE	USA	14/125905
TRIEP.132WO	INJECTION NEEDLE, DEVICE, IMMUNOGENIC COMPOSITIONS AND METHOD OF USE	WO	PCT/US2013/063461

TRIEP.134WO	IMMUNOGENIC COMPOSITIONS FOR INHIBITING HEPATITIS D VIRUS	WO	PCT/US2014/037918
TRIEP.136WO	TREATMENT OF HEPATITIS D VIRUS INFECTIONS BY REDIRECTION OF T CELLS	WO	PCT/US2014/056158

19499550
120914

